Overview

PharmacofMRI of Anxiolytic Medications (Pregabalin)

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Anti-Anxiety Agents
Pregabalin